Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.01 par value
|
NLNK
|
The Nasdaq Global Market
|
•
|
To elect the nominees for director, Matthew L. Sherman, M.D. and Nicholas N. Vahanian, M.D., nominated by the Board of Directors of the Company (the "
Board
"), to serve until the 2022 Annual Meeting of Stockholders;
|
•
|
To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement, filed with the Securities and Exchange Commission on April 5, 2019 (the "
Proxy Statement
");
|
•
|
To amend the Company's 2009 Equity Incentive Plan to, among other things, extend the term of the 2009 Equity Incentive Plan;
|
•
|
To approve a stock option exchange program, pursuant to which employees and directors may exchange eligible stock options for new stock options with an exercise price equal to the fair market value of the Company's common stock at the time of the exchange;
|
•
|
To approve stock options grants to Chief Executive Officer Charles J. Link, Jr., M.D. and President Nicholas N. Vahanian, M.D.; and
|
•
|
To ratify the selection by the Audit Committee of the Board of KPMG, LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2019.
|
•
|
elected Matthew L. Sherman, M.D. and Nicholas N. Vahanian, M.D. as directors of the Company;
|
•
|
approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as set forth in the Proxy Statement;
|
•
|
approved the amendment to the Company's 2009 Equity Incentive Plan as disclosed in the Proxy Statement:
|
•
|
approved the stock option exchange program as disclosed in the Proxy Statement;
|
•
|
approved the stock option grants to the Chief Executive Officer and President as disclosed in the Proxy Statement; and
|
•
|
ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2019.
|
|
Election of Directors
|
For
|
Withheld
|
Broker Non-Votes
|
1.
|
Matthew L. Sherman, M.D.
|
16,595,714
|
509,411
|
13,759,765
|
|
Nicholas N. Vahanian, M.D.
|
16,215,178
|
889,947
|
13,759,765
|
|
|
For
|
Against
|
Abstentions
|
Broker Non-Votes
|
2.
|
Approval, on an advisory basis, of the compensation of the Company's named executive officers
|
15,710,870
|
1,334,963
|
59,292
|
13,759,765
|
|
|
For
|
Against
|
Abstentions
|
6.
|
Ratification of KPMG LLP as independent registered public accounting firm for the Company's fiscal year ending December 31, 2019
|
30,267,560
|
532,277
|
65,053
|
|
NewLink Genetics Corporation
|
|
|
|
|
By:
|
/s/ Carl W. Langren
|
|
Carl W. Langren
|
Its:
|
Chief Financial Officer
|